# Breath Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/breath-therapeutics-b-v

- Industry: Pharmaceuticals
- Headquarters: Munich, Germany
- Website: www.breath-therapeutics.com
- Total disclosed funding: $46M
- Latest round: Series A (Mar 8, 2017)
- Investors on record: 3

## About

Breath Therapeutics B.V. is a pioneering biotechnology firm focused on developing innovative therapies for severe respiratory diseases, including Bronchiolitis Obliterans Syndrome, to enhance patient care and health outcomes.Founded in 2016 in Munich, Germany, Breath Therapeutics specializes in respiratory therapies. The company was acquired by Zambon in July 2019 for EUR 140 million, with potential additional payments of EUR 360 million based on milestones. The acquisition marks a significant shift in their operational strategy as they join forces with a larger organization to broaden their impact. Zambon, a well-established name in the pharmaceutical industry, aims to leverage Breath Therapeutics' innovative pipeline for specialized respiratory conditions.Breath Therapeutics offers Liposomal Cyclosporine A for Inhalation (L-CsA-i), targeting Bronchiolitis Obliterans Syndrome (BOS), a serious condition afflicting lung transplant patients. They are also developing treatments for Non-Cystic Fibrosis Bronchiectasis (NCFB), focusing on chronic airway inflammation. These products primarily cater to healthcare providers and hospitals, reflecting their growth strategy in the U.S. market while exploring global expansion opportunities.Breath Therapeutics operates on a B2B revenue model, primarily through direct sales of L-CsA-i to healthcare institutions. They establish partnerships with hospitals and healthcare providers, ensuring patients have access to crucial treatments. Revenue from these sales supports ongoing research and development initiatives aimed at expanding their therapeutic offerings and enhancing patient care.Breath Therapeutics plans to leverage its recent acquisition by Zambon to accelerate the development of new therapeutic products, focusing on launching new treatments by 2022. The company aims to expand its presence into additional markets, particularly across Europe and North America, by 2023. The EUR 140 million from the acquisition will be utilized to support these growth initiatives, including increasing R&D capabilities and enhancing marketing efforts to reach broader patient populations.

## Funding rounds

- Series A, Mar 8, 2017, $46M — Sofinnova Partners, Gilde Healthcare, Gimv

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A
- Gimv (https://capitalatlas.ai/funds/gimv) — Series A